{
    "clinical_study": {
        "@rank": "68858", 
        "acronym": "STRUT-OCT", 
        "arm_group": [
            {
                "arm_group_label": "Xience EES", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging"
            }, 
            {
                "arm_group_label": "Resolute Integrity ZES", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging"
            }, 
            {
                "arm_group_label": "Promus Element EES", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is proposed as a 48-patient randomized-controlled pilot study that will use\n      Optical Coherence Tomography (OCT) imaging to compare stent strut coverage and malapposition\n      of three second-generation Drug Eluting Stents (DES) [Xience EES (Abbott Vascular, Santa\n      Clara, CA), Resolute Integrity ZES (Medtronic, Minneapolis, MN) and Promus Element EES\n      (Boston Scientific, Natick, MA)] at 6 weeks post implantation.\n\n      Study Hypothesis is that the rates of stent strut coverage and malapposition of the Xience\n      EES, Promus EES and will be similar to each other and improved (higher rates of stent strut\n      coverage and lower rates of malapposition) compared to the Resolute ZES at 6 weeks\n      post-implantation."
        }, 
        "brief_title": "Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)", 
        "condition": [
            "Drug Eluting Stents (DES)", 
            "Percutaneous Coronary Intervention (PCI)", 
            "Uncovered and Malapposed Stent Struts", 
            "Optical Coherence Tomography (OCT)"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age greater than or equal to 18 years\n\n          2. Clinical need for percutaneous coronary intervention using either a Xience, Promus\n             Element, or Resolute Integrity drug-eluting stent using optical coherence tomography\n             optimization\n\n          3. Native coronary artery de novo lesion with \u226570% angiographic percent diameter\n             stenosis by visual estimation\n\n          4. Target vessel reference diameter between 2.5 and 4.0 mm by visual estimate\n\n          5. Target lesion \u226428 mm in length by visual estimate\n\n          6. Agree to participate and provide informed consent\n\n        Exclusion Criteria:\n\n        1.Presentation with acute ST-elevation myocardial infarction (defined as\n        electrocardiographic (ECG) ST-elevation \u2265 2 mm in 2 or more contiguous ECG leads along\n        with symptoms compatible with ischemia)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "89 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962740", 
            "org_study_id": "13-043"
        }, 
        "intervention": {
            "arm_group_label": [
                "Xience EES", 
                "Resolute Integrity ZES", 
                "Promus Element EES"
            ], 
            "intervention_name": "Drug-eluting stent implantation", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75216"
                }, 
                "name": "VA North Texas Health Care System"
            }, 
            "investigator": {
                "last_name": "Shuaib Abdullah, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Serial Evaluation of Drug-Eluting Stents Using OCT", 
        "overall_contact": {
            "email": "Shuaib.Abdullah@va.gov", 
            "last_name": "Shuaib Abdullah, MD", 
            "phone": "214-8571458"
        }, 
        "overall_contact_backup": {
            "email": "Anna.Kotsia@va.gov", 
            "last_name": "Anna Kotsia, MD", 
            "phone": "214-8572529"
        }, 
        "overall_official": {
            "affiliation": "North Texas Veterans Healthcare System", 
            "last_name": "Shuaib Abdullah, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: VA North Texas Health Care System Dallas VAMC Institutional Review Board", 
                "United States: VA North Texas Health Care System Dallas VAMC Research and Development Committee", 
                "United States: Independent Data Safety Monitoring Board"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Stent Strut Coverage", 
                "safety_issue": "No", 
                "time_frame": "6 weeks post-implantation"
            }, 
            {
                "measure": "Stent Strut Malapposition", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks post-implantation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962740"
        }, 
        "responsible_party": {
            "investigator_affiliation": "North Texas Veterans Healthcare System", 
            "investigator_full_name": "Shuaib Abdullah, MD", 
            "investigator_title": "Cardiologist; Assistant Professor, Division of Cardiology, Internal Medicine, UT Southwestern Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "North Texas Veterans Healthcare System", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "North Texas Veterans Healthcare System", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}